Heidelberg Pharma AG (HPHA.DE) News
Follow Heidelberg Pharma AG (HPHA.DE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Heidelberg Pharma sets 175 µg/kg RP2D for pamlectabart tismanitin in Phase I/IIa multiple myeloma trial
Heidelberg Pharma presented new Phase I/IIa data on pamlectabart tismanitin at the IMS Annual Meeting 2026. The trial supported a Phase 2 dose selection, with safety remaining favorable and no dose-limiting ceiling ident
NEWS | Sep 24, 2026, 08:35 AM UTC
L
EQS — News: Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026
EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026 24.09.2026 / 10:33 CET/CEST The issuer
CENTRAL_BANK | Sep 24, 2026, 08:35 AM UTC